Moreover, recent advancements have demonstrated that combining BRAF/MEK inhibitors with immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, can further enhance therapeutic efficacy by targeting complementary mechanisms, thereby overcoming resistance and improving survival outcomes in melanoma patients. The gene discussed is MAP2K7; the disease is melanoma.